verezdoВестник репродуктивного здоровьяBulletin of Reproductive Health2075-65692310-421XEndocrinology Research Centre (Moscow)10.14341/brh2007133-41verezdo-8510Research ArticleСтатьиArticlesРезистентность к терапии агонистами дофамина у пациентов с гиперпролактинемиейRezistentnost' k terapii agonistami dofamina u patsientov s giperprolaktinemieyМельниченкоГ АMel'nichenkoG A-ДзерановаЛ КDzeranovaL K-БарминаИ ИBarminaI I-КадашевБ АKadashevB A-АстафьеваЛ ИAstaf'evaL I-ШишкинаЛ ВShishkinaL V-Эндокринологический научный центр Росмедтехнологий20071509200701№1 (2007)3341Copyright © Мельниченко Г.А., Дзеранова Л.К., Бармина И.И., Кадашев Б.А., Астафьева Л.И., Шишкина Л.В., 20072007Мельниченко Г.А., Дзеранова Л.К., Бармина И.И., Кадашев Б.А., Астафьева Л.И., Шишкина Л.В.Mel'nichenko G.A., Dzeranova L.K., Barmina I.I., Kadashev B.A., Astaf'eva L.I., Shishkina L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.vrz-endojournals.ru/jour/article/view/8510

Проблема гиперпролактинемии сохраняет свою актуальность как для эндокринологов, так и акушеров-гинекологов. Около 30% случаев бесплодия ассоциированы с гиперпролактинемией. Распространенность данной патологии в популяции составляет 0,5% у женщин и 0,07% у мужчин; у женщин она более чем в 10 раз выше, чем у мужчин [1]. Наибольшая частота развития гиперпролактинемии отмечается у женщин в возрасте 25—40 лет.В значительном числе случаев патологическая гиперпролактинемия ассоциирована с наличием пролактинсекретирующей аденомы гипофиза. Пролактиномы, в зависимости от размера, разделяют на микроаденомы (менее 1 см) и макроаденомы (более 1 см). Наличие и характер аденомы гипофиза являются одними из ключевых факторов в определении тактики ведения таких пациентов.

ReferencesMyai K., Ichinara K., Kondo K., Mori S. Asymptomatiс hyperprolactinemia and prolactinoma in general population-mass screening by paired assays of serum prolactine. Clin Endocrinol 1986; 25: 549— 554.Myai K., Ichinara K., Kondo K., Mori S. Asymptomatiс hyperprolactinemia and prolactinoma in general population-mass screening by paired assays of serum prolactine. Clin Endocrinol 1986; 25: 549— 554.Вакс В.В. гиперпролактинемия: причины, клиника, диагностика и лечение. Consilium Medicum 2001; 3 (11).Вакс В.В. гиперпролактинемия: причины, клиника, диагностика и лечение. Consilium Medicum 2001; 3 (11).Дедов И.И., мельниченко г.А., Романцова т.И. Синдром гиперпролактинемии. м 2004.Дедов И.И., мельниченко г.А., Романцова т.И. Синдром гиперпролактинемии. м 2004.Casanueva F., Molitch M., Schlechte J. et al. Guidelines of the piuitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006; 65: 265—273.Casanueva F., Molitch M., Schlechte J. et al. Guidelines of the piuitary Society for the diagnosis and management of prolactinomas. Clin Endocrinol 2006; 65: 265—273.Molitch M.E. Pharmacologic resistance in prolactinoma patients. Pituitary 2005; 8: 43—52.Molitch M.E. Pharmacologic resistance in prolactinoma patients. Pituitary 2005; 8: 43—52.Дзеранова л.к., марова Е.И., Сергеева Н.И. медикаментозное лечение пролактином. В кн.: Актуальные проблемы нейроэндокринологии. м 2003; 167—172.Дзеранова л.к., марова Е.И., Сергеева Н.И. медикаментозное лечение пролактином. В кн.: Актуальные проблемы нейроэндокринологии. м 2003; 167—172.Brue T., Pellegrini I., Priou A. et al. Prolactinomas and resistance to dopamine agonists. Horm Res 1992; 38: 84—89.Brue T., Pellegrini I., Priou A. et al. Prolactinomas and resistance to dopamine agonists. Horm Res 1992; 38: 84—89.Di Sarno A., Landi M.L., Cappabianca P. et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. JCE&M 2001; 86: 5256—5261.Di Sarno A., Landi M.L., Cappabianca P. et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. JCE&M 2001; 86: 5256—5261.Webster J., Piscitelli G., Polli A. et al. A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea. NEJM 1994; 331: 904—909.Webster J., Piscitelli G., Polli A. et al. A Comparison of Cabergoline and Bromocriptine in the Treatment of Hyperprolactinemic Amenorrhea. NEJM 1994; 331: 904—909.Verhelst J., Abs R., Maiter D. Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients. JCE&M 1999; 84: 2518—2522.Verhelst J., Abs R., Maiter D. Cabergoline in the Treatment of Hyperprolactinemia: A Study in 455 Patients. JCE&M 1999; 84: 2518—2522.Molitch M.E. Dopamine resistance of prolactinomas. Pituitary 2003; 6: 19—27.Molitch M.E. Dopamine resistance of prolactinomas. Pituitary 2003; 6: 19—27.Ferrari C.I., Abs R., Bevan J.S. et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997; 46: 409—413.Ferrari C.I., Abs R., Bevan J.S. et al. Treatment of macroprolactinoma with cabergoline: a study of 85 patients. Clin Endocrinol (Oxf) 1997; 46: 409—413.Delgrange E., Duprez T., Maiter D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol (Oxf) 2006; 64: 456—462.Delgrange E., Duprez T., Maiter D. Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol (Oxf) 2006; 64: 456—462.Delgrange E., Sassolas G., Perrin G. et al. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 2005; 147: 751—758.Delgrange E., Sassolas G., Perrin G. et al. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochir (Wien) 2005; 147: 751—758.Pellegrini I., Rasolonjanahary R., Gunz G. et al. Resistance to bromocriptine in prolactinomas. JCE&M 1989; 69: 500—509.Pellegrini I., Rasolonjanahary R., Gunz G. et al. Resistance to bromocriptine in prolactinomas. JCE&M 1989; 69: 500—509.Caccavelli L., Feron F., Morange I. et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994; 60: 314—322.Caccavelli L., Feron F., Morange I. et al. Decreased expression of the two D2 dopamine receptor isoforms in bromocriptine-resistant prolactinomas. Neuroendocrinology 1994; 60: 314—322.Caccavelli L., Jaquet P., Kordon C. et al. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol 1996; 10: 737—746.Caccavelli L., Jaquet P., Kordon C. et al. Alteration of G alpha subunits mRNA levels in bromocriptine resistant prolactinomas. J Neuroendocrinol 1996; 10: 737—746.Lamberts S.W., Verleun T., Hofland L., Oosterom R. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. JCE&M 1986; 63: 1342—1347.Lamberts S.W., Verleun T., Hofland L., Oosterom R. Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells. JCE&M 1986; 63: 1342—1347.Luciano A., Sherman B., Chapler F. et al. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 1985; 65: 506—510.Luciano A., Sherman B., Chapler F. et al. Hyperprolactinemia and contraception: a prospective study. Obstet Gynecol 1985; 65: 506—510.Garcia M.M., Kapcala L.P. Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 1995; 18: 450—455.Garcia M.M., Kapcala L.P. Growth of a microprolactinoma to a macroprolactinoma during estrogen therapy. J Endocrinol Invest 1995; 18: 450—455.Abech D.D., Moratelli H.B., Leite S.C., Oliveira M.C. Effects of estrogen replacement therapy on pituitary size, prolactin and thyroid-stimulating hormone concentrations in menopausal women. Gynecol Endocrinol 2005; 21: 223—236.Abech D.D., Moratelli H.B., Leite S.C., Oliveira M.C. Effects of estrogen replacement therapy on pituitary size, prolactin and thyroid-stimulating hormone concentrations in menopausal women. Gynecol Endocrinol 2005; 21: 223—236.Touraine P., Deneux C., Plu-Bureau G. et al. Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia. J Endocrinol Invest 1998; 21: 732—736.Touraine P., Deneux C., Plu-Bureau G. et al. Hormonal replacement therapy in menopausal women with a history of hyperprolactinemia. J Endocrinol Invest 1998; 21: 732—736.Corenblum B., Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993; 59: 671—673.Corenblum B., Donovan L. The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil Steril 1993; 59: 671—673.Testa G., Vegetti W., Motta T. et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 1998; 58: 69—73.Testa G., Vegetti W., Motta T. et al. Two-year treatment with oral contraceptives in hyperprolactinemic patients. Contraception 1998; 58: 69—73.Suliman Abdulwahab M., Smith Thomas P., Gibney J., McKenna T. J. Frequent Misdiagnosis and Mismanagement of Hyperprolactinemic Patients before the Introduction of Macroprolactin Screening: Application of a New Strict Laboratory Definition of Macroprolactinemia. Clin Chem 2003; 49: 1504— 1509.Suliman Abdulwahab M., Smith Thomas P., Gibney J., McKenna T. J. Frequent Misdiagnosis and Mismanagement of Hyperprolactinemic Patients before the Introduction of Macroprolactin Screening: Application of a New Strict Laboratory Definition of Macroprolactinemia. Clin Chem 2003; 49: 1504— 1509.Gillam M.P., Middler S., Freed D.J., Molitch M.E. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 2002; 87: 4447—4451.Gillam M.P., Middler S., Freed D.J., Molitch M.E. The novel use of very high doses of cabergoline and a combination of testosterone and an aromatase inhibitor in the treatment of a giant prolactinoma. J Clin Endocrinol Metab 2002; 87: 4447—4451.Olafsdottir A., Schlechte J. Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2006; 2: 552—561.Olafsdottir A., Schlechte J. Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2006; 2: 552—561.Colao A., Di Sarno A., Landi M.L. et al. Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients. JCE&M 2000; 85: 2247—2252.Colao A., Di Sarno A., Landi M.L. et al. Macroprolactinoma Shrinkage during Cabergoline Treatment Is Greater in Naive Patients Than in Patients Pretreated with Other Dopamine Agonists: A Prospective Study in 110 Patients. JCE&M 2000; 85: 2247—2252.Colao A., Di Sarno A., Sarnacchiaro F. et al. Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment. JCE&M 1997; 83: 876—883.Colao A., Di Sarno A., Sarnacchiaro F. et al. Prolactinomas Resistant to Standard Dopamine Agonists Respond to Chronic Cabergoline Treatment. JCE&M 1997; 83: 876—883.Molitch M.E., Thorner M.O., Wilson C. The Case for Initial Surgical Removal of Certain Prolactinomas. JCE&M 1997; 8 996—1000.Molitch M.E., Thorner M.O., Wilson C. The Case for Initial Surgical Removal of Certain Prolactinomas. JCE&M 1997; 8 996—1000.Hamilton D.K., Vance M.L., Boulos P.T., Laws E.R. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005; 8: 53—60.Hamilton D.K., Vance M.L., Boulos P.T., Laws E.R. Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intolerance to dopamine agonists. Pituitary 2005; 8: 53—60.Spritzer P.M., Ribeiro M.F., Oliveira M.C. et al. Effects of tamoxifen on serum prolactin levels, pituitary immunoreactive prolactin cells and uterine growth in estradiol-treated ovariectomized rats. Horm Metab Res 1996; 28: 171—176.Spritzer P.M., Ribeiro M.F., Oliveira M.C. et al. Effects of tamoxifen on serum prolactin levels, pituitary immunoreactive prolactin cells and uterine growth in estradiol-treated ovariectomized rats. Horm Metab Res 1996; 28: 171—176.Lamberts S.W., Verleun T., Oosterom R. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 1982; 34: 339—342.Lamberts S.W., Verleun T., Oosterom R. Effect of tamoxifen administration on prolactin release by invasive prolactin-secreting pituitary adenomas. Neuroendocrinology 1982; 34: 339—342.Lasco A., Cannavo S., Gaudio A. et al. Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. Eur J Endocrinol 2002; 147: 461—465.Lasco A., Cannavo S., Gaudio A. et al. Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women. Eur J Endocrinol 2002; 147: 461—465.Faupel-Badger J.M., Prindiville S.A., Venzon D. et al. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 16: 1153—1158.Faupel-Badger J.M., Prindiville S.A., Venzon D. et al. Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer. Cancer Epidemiol Biomarkers Prev 2006; 16: 1153—1158.Cheng W.C., Yen M.L., Hsu S.H. et al. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Endocrine 2004; 23: 215—218.Cheng W.C., Yen M.L., Hsu S.H. et al. Effects of raloxifene, one of the selective estrogen receptor modulators, on pituitary-ovary axis and prolactin in postmenopausal women. Endocrine 2004; 23: 215—218.Goffin V., Bernichtein S., Touraine P., Kelly P.A. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005; 26: 400—422.Goffin V., Bernichtein S., Touraine P., Kelly P.A. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005; 26: 400—422.Hofland L.J., van der Hoek J., van Koetsveld P.M. et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormoneand prolactin-secreting pituitary adenomas in vitro. JC E&M 2004; 89: 1577—1585. поступила 07.07.07Hofland L.J., van der Hoek J., van Koetsveld P.M. et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormoneand prolactin-secreting pituitary adenomas in vitro. JC E&M 2004; 89: 1577—1585. поступила 07.07.07

The authors declare that there are no conflicts of interest present.